As shown in Figure 14, the levels of PINK1 and CADH4 were significantly increased in TBN-treated group when compared with AD control group, which was consistent with the results of proteomic analysis that TBN significantly upregulated the expression of PINK1 and CADH4 (Table 1). The gene discussed is PINK1; the disease is Alzheimer disease.